Clinical Trial Details

Short Title
this study is for patients diagnosed with T-cell Acute Lymphoblastic Leukemia (ALL).
Official Title

Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma

Description

This research study is for patients diagnosed with T-cell Acute Lymphoblastic Leukemia (ALL).  ALL is a type of cancer that occurs in the bone marrow.  It is a disease in which there is an uncontrolled growth of abnormal white blood cells, referred to as blasts.  These abnormal cells crowd out the normal cells in the bone marrow.  Sometimes these blasts cells can be found in the brain, spinal cord, and /or other organs of the body.  Participants in this study have a type of ALL that places them in the Intermediate Risk group of T-cell ALL, which means that they have entered remission (less than 5% blasts in the bone marrow at the end of Induction therapy and 0.1-1% blasts detected by a test called flow cytometry) and are not in the Low or High Risk groups. Most subjects (about 60%) with T-cell ALL fall into the Intermediate Risk group.

 

Start Date
May 29, 2008
End Date
May 29, 2018
Gender Preference
None
Age Group
1 - 30 years
Principal Investigator
Ayman El-Sheikh, MD
Contact Info

Julie de la Garza, (319) 356-3749

Department
Hematology/Oncology
Keywords
200710790 ; Acute Lymphoblastic Leukemia ; ALL ; cancer ; El-Sheikh ; leukemia ; lymphoma ; pediatric ; phase three ; T-cell Lymphoblastic Lymphoma ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x